Biotech Sector Continues Strong Rebound! CSOP Hang Seng Biotech ETF (03174.HK) Surges Over 6% in Afternoon Trading

NewTimeSpace News: April 1 – The pharmaceutical sector maintained its strong momentum with another breakout rally today. Innovative drug concepts remained highly active: Asymchem (002821.SZ) hit the daily limit up, BaiLiTianHeng (688506.SH) surged over 11%, while RemeGen (09995.HK/688331.SH) and Junshi Biosciences (01877.HK/688180.SH) jumped more than 9%.

CSOP Hang Seng Biotech ETF (03174.HK) advanced over 6% in afternoon trading, accumulating gains of nearly 10% across the past five trading sessions.

The sector's resilience stems from a convergence of catalysts: its war-immune defensive characteristics, earnings inflection points, accelerated internationalization ("going global"), and major industry conferences. These factors have fortified the pharmaceutical sector with strong defensive attributes amid recent market turbulence, establishing it as a primary destination for capital rotation.

Managed by CSOP Asset Management and listed on the Hong Kong Stock Exchange, CSOP Hang Seng Biotech (03174.HK) tracks the Hang Seng Biotechnology Index. This ETF offers concentrated exposure to Hong Kong-listed biotech leaders, characterized by high volatility and significant elasticity—suitable for investors with conviction in innovative drugs, CXO (contract research and manufacturing organizations), vaccines, and gene therapy sectors.

Data Catalyst:China’s innovative drug outbound licensing transactions exceeded USD 60 billion in Q1 2026 alone—approaching nearly half of the total for full-year 2025—signaling faster-than-expected globalization progress.

Conference Catalyst:The AACR (American Association for Cancer Research) Annual Meeting convenes April 17-22 in San Diego, with over 140 Chinese pharmaceutical companies presenting 250+ innovative drug candidates spanning radiopharmaceuticals, DACs (Degraders-Antibody Conjugates), cell therapy, and mRNA technologies. Multiple firms have already released positive clinical data ahead of the conference.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.